Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

By afschroeder • April 30, 2026

Shachar EK, Silverstein J, Kwan L, Salani R, Karlan BY, Chase DM. Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers? Gynecol Oncol. 2026 Apr 28;209:26-32. doi: 10.1016/j.ygyno.2026.04.011. Epub ahead of print. PMID: 42054783.

Tags: age, antibody drug conjugates, Ethnicity, gynecologic cancer, Hematology/Oncology, Publications, Race, Underrepresented minorities

Related Posts

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]